In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Adding to its US regulatory clearance in August, the European Commission (EC) has now also granted conditional marketing authorization for Elrexfio (elranatamab), from US pharma giant Pfizer. 8 December 2023
Biotechnology
British drugmaker AstraZeneca has published research in The Lancet outlining the impact of Fasenra (benralizumab) in severe eosinophilic asthma. 8 December 2023
Pharmaceutical
New Jersey, USA-based Amneal Pharmaceuticals has agreed terms for a licensing deal with Portugal's largest drugmaker, BIAL. 8 December 2023
Pharmaceutical
Japanese drugmaker Daiichi Sankyo announced that its subsidiary Plexxikon and Swiss pharma giant Novartis have settled the patent infringement lawsuit against Novartis regarding the sale of the latter’s BRAF inhibitor Tafinlar (dabrafenib) in the USA. 8 December 2023
Biotechnology
China’s National Medical Products Administration (NMPA) has approved the supplemental biologics license application (sBLA) for Cejemly (sugemalimab) alongside fluorouracil and platinum-based chemotherapy as a first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). 8 December 2023
Biotechnology
US biotech Novavax has an advanced purchase agreement (APA) with the European Commission and an arrangement with the UK for the supply of the firm’s COVID-19 vaccine, developed with its Matrix-M adjuvant. 8 December 2023
Biotechnology
Australian regulator the Therapeutic Goods Administration (TGA) says that its investigation into the risk of myocardial infarction and stroke in patients taking romosozumab (Evenity) found that stronger warnings regarding these risks were needed in the Product Information (PI) and Consumer Medicine (CMI) Information external sites. 8 December 2023
Pharmaceutical
In the USA, the Biden administration announced a framework yesterday that proposes including prices as a factor when deciding if the public can easily obtain a taxpayer-funded drug and allowing government agencies to license the patent behind the product to another party if the cost is determined to be too high. 8 December 2023
Pharmaceutical
AstraZeneca and development partner Merck & Co have secured a positive reimbursement decision for Lynparza (olaparib) in the UK. 8 December 2023
Biotechnology
German biotech BioNTech revealed that it has signed a multi-year strategic partnership with the State of Victoria in Australia to strengthen the local mRNA ecosystem and facilitate innovations deriving from it. 8 December 2023
Pharmaceutical
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, announced today that it has appointed Rayna Sethi Herman as chief commercial officer. 8 December 2023
Pharmaceutical
French drugmaker Ipsen has had a busy Thursday - announcing an update on its overall outlook and elafibranor, a key pipeline prospect. 7 December 2023
Biotechnology
French pharma major Sanofi has provided an update from its Phase III IMROZ trial. 7 December 2023
Pharmaceutical
Since the US Food and Drug Administration’s acceptance of Madrigal Pharmaceutical’s new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September 2023, the company has taken steps to fortify its leadership and financial position to gear up for the imminent launch of resmetirom. 7 December 2023
Pharmaceutical
US hematology company Syros Pharmaceuticals has announced “strong and encouraging” initial data from its ongoing mid-stage trial, SELECT-AML-1. 7 December 2023
Biotechnology
Netherlands-based Synaffix, which was recently acquired by Swiss contract development and manufacturing organization (CDMO Lonza, said today it has expanded its licensing agreement with China’s Innovent Biologics. 7 December 2023
Biotechnology
Oncolytic immunotherapy company Replimune Group has announced results from the primary analysis of the CERPASS trial. 7 December 2023
Biotechnology
Shares of Switzerland-based clinical-stage drug developer Pharvaris rose by as much as 42% Wednesday morning, as it announced positive top-line data from the CHAPTER-1 Phase II clinical study meeting its primary endpoint, with deucrictibant. 7 December 2023
Pharmaceutical
After eight years of follow-up, Eli Lilly has revealed that a statistically -significant overall survival (OS) improvement was not reached for patients in the MONARCH 3 trial. 7 December 2023
Biotechnology
At an investor R&D day in New York, French drugmaker Sanofi provided an update on developments regarding its pipeline and what it expects to be key growth drivers in the future. 7 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze